Personally Furnishing Buprenorphine Products by Opioid Treatment Programs

Updated 3/18/2020

To address patient access to medication assisted treatment during the COVID-19 outbreak, the State of Ohio Board of Pharmacy has adopted the following guidance authorizing prescribers working in an opioid treatment program licensed as a terminal distributor of dangerous drugs to temporarily delegate personally furnishing of buprenorphine products to nurses licensed under Chapter 4723. of the Revised Code.

This guidance is being issued in accordance with a Board resolution adopted on March 2, 2020.

In addition to the delegation authorized under rule 4729:5-21-02 of the Administrative Code, a prescriber at an opioid treatment program may delegate the act of personally furnishing buprenorphine for the purpose of treating drug dependence or addiction to a nurse (RN/LPN) licensed under Chapter 4723. of the Revised Code. The nurse must have a documented order by a prescriber and must document the act of personally furnishing using positive identification. The nurse shall be responsible for ensuring the drug is properly labeled in accordance with rule 4729:5-21-02 of the Administrative Code.

This guidance shall remain in effect until rescinded by the Board.